Market closed · data as of 27 Aug 2026 · source NSE via Alphave. Open the live chart →
Biocon is a biopharmaceutical company with three arms: biosimilars (global monoclonal antibodies and insulins via Biocon Biologics, which acquired Viatris's biosimilars business), generic APIs and formulations, and contract research through listed subsidiary Syngene International. Biosimilars — including trastuzumab, adalimumab, and insulin glargine/aspart with US and EU approvals — are the largest and most strategic segment, alongside a GLP-1 generics pipeline. Deleveraging Biocon Biologics after the Viatris deal has been a central financial theme.
India's leading biosimilars company and among the few global players with approved biosimilar insulins and mAbs in the US.
Biocon Ltd. is a constituent of NIFTY 200, NIFTY 500, NIFTY HEALTHCARE, NIFTY MIDCAP 100, NIFTY MIDCAP 150, NIFTY PHARMA. See where it sits on the market heatmap →
Consolidated annual figures taken from Biocon Ltd.'s own filed statements — not estimates, and not restated by us. The most recent period shown is FY26 (year ended 31 Mar 2026).
Per-share figures are not restated. Shares outstanding changed from 120.06 crore to 162.10 crore in FY26, consistent with a bonus issue or stock split. Each year's EPS and book value below are as that year was filed, on that year's share count — so the per-share line falls across FY26 even where profit did not. Compare the absolute figures (EBITDA, free cash flow, total debt) and the margins across that boundary, not the per-share ones.
| Metric | FY26 | FY25 | FY24 |
|---|---|---|---|
| EPS (basic, ₹) | 2.82 | 8.46 | 8.55 |
| Book value / share (₹) | 225.92 | 230.82 | 210.52 |
| Return on equity | 1.1% | 3.7% | 4.0% |
| Return on capital employed | 3.0% | 3.3% | 4.3% |
| Operating margin | 8.8% | 9.7% | 11.7% |
| Net margin | 2.2% | 9.4% | 8.8% |
| EBITDA | ₹3,455 Cr | ₹3,166 Cr | ₹3,299 Cr |
| Free cash flow | ₹82 Cr | ₹1,718 Cr | ₹1,022 Cr |
| Total debt | ₹14,825 Cr | ₹17,756 Cr | ₹15,730 Cr |
| Debt to equity | 0.40 | 0.64 | 0.62 |
| Interest coverage | 1.5 | 1.6 | 1.8 |
| Current ratio | 1.22 | 1.14 | 0.99 |
| Shares outstanding | 1,62,10,00,000 | 1,20,06,00,000 | 1,20,06,00,000 |
Open the full income statement, balance sheet and cash flow for BIOCON →
As disclosed for the quarter ended 30 Jun 2026.
Institutional ownership changes quarter to quarter. See daily FII and DII flows across the market →
Companies Alphave classifies in the same sub-sector, closest by market capitalisation.